Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 36
- Registration Number
- NCT02351037
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 66
- Registration Number
- NCT02345863
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRecurrent Splenic Marginal Zone LymphomaWaldenstrom MacroglobulinemiaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Grade 1 Follicular LymphomaRefractory Lymphoplasmacytic LymphomaRefractory Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Grade 3 Follicular Lymphoma
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 65
- Registration Number
- NCT02332980
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 144
- Registration Number
- NCT02329847
A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT02321540
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
- Conditions
- Interventions
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 32
- Registration Number
- NCT02315768
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
- Conditions
- Interventions
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 109
- Registration Number
- NCT02315326
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-12-05
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT02309580
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Jennifer Woyach
- Target Recruit Count
- 34
- Registration Number
- NCT02303392
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT02301156
- Locations
- 🇮🇱
TG Therapeutics Investigational Trial Site, Ashkelon, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.